Peter C. Wendell - 30 Jun 2021 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role: Director
Signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Peter C. Wendell
Issuer symbol: MRK
Transactions as of: 30 Jun 2021
Net transactions value: +$30,000
Form type: 4
Filing time: 02 Jul 2021, 09:40:10 UTC
Previous filing: 02 Jun 2021
Next filing: 01 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRK	Common Stock						1,000	30 Jun 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRK	Phantom Stock	Award	$30,000	+386	+0.36%	$77.77	107,613	30 Jun 2021	Common Stock	386		Direct	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1-for-1
F2	Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3	Holdings include shares acquired in dividend reinvestment transactions.
F4	Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.